Date: 2016-11-10
Type of information: R&D agreement
Compound: mechanisms of response and resistance in patients whose cancer is being treated with checkpoint inhibitor-based immunotherapies
Company: BMS (USA - NY) The Johns Hopkins University (USA - MD)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: * On November 10, 2016, BMS announced that the company has entered into a five-year research collaboration with the Johns Hopkins University. The collaboration is designed to identify mechanisms of response and resistance in patients whose cancer is being treated with checkpoint inhibitor-based immunotherapies, including Opdivo® (nivolumab) monotherapy, or Opdivo® in combination with Yervoy® (ipilimumab) or other investigational immunotherapies. Under the collaboration, BMS and Johns Hopkins’ scientists will launch an interdisciplinary research program that will study patient tumor samples in four primary research areas: characterization of tumor antigens and tumor antigen-specific T-cells, multifaceted profiling of the tumor microenvironment, assessment of microbiome components that modulate systemic anti-tumor immunity, and elucidation of novel tumor and immuno-metabolism factors that modify responsiveness to immunotherapy. BMS and Johns Hopkins will also explore several early-stage clinical trials primarily focused on, but not limited to, the study of neoadjuvant immunotherapeutic interventions. This agreement builds on the productive track record of collaboration between BMS and the Johns Hopkins Kimmel Cancer Center- both leaders in the transformative field of Immuno-Oncology. Johns Hopkins is a founding member of the International Immuno-Oncology Network (II-ON), a global collaboration between BMS and 13 academia centers that aims to further the scientific understanding of immuno-oncology. The two organizations also entered into an agreement in November 2015 as part of BMS’ Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.
Financial terms:
Latest news:
